Bristol Myers Squibb (BMY) Change in Acquisitions & Divestments (2009 - 2026)

Bristol Myers Squibb (BMY) has 18 years of Change in Acquisitions & Divestments data on file, last reported at $391.0 million in Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $391.0 million, up 77.73% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.1 billion (up 260.67% YoY), and the FY2025 annual result was $2.0 billion, up 76.02% from the prior year.
• Change in Acquisitions & Divestments fell to $391.0 million in Q1 2026 per BMY's latest filing, from $402.0 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $5.1 billion in Q3 2022 and troughed at -$762.0 million in Q3 2024.
• A 5-year average of $625.4 million and a median of $391.0 million in 2026 frame the typical range for Change in Acquisitions & Divestments.
• The sharpest annual moves came in 2023 and 2024: Change in Acquisitions & Divestments surged 2750.0% in 2023, then plunged 221.92% in 2024.
• A 5-year view of Change in Acquisitions & Divestments shows it stood at $1.2 billion in 2022, then sank by 96.6% to $41.0 million in 2023, then jumped by 2490.24% to $1.1 billion in 2024, then plunged by 62.15% to $402.0 million in 2025, then dropped by 2.74% to $391.0 million in 2026.
• Business Quant data shows BMY's Change in Acquisitions & Divestments at $391.0 million in Q1 2026, $402.0 million in Q4 2025, and $829.0 million in Q3 2025.